Coronary Artery Calcification, Cardiovascular Events, and Death: A Prospective Cohort Study of Incident Patients on Hemodialysis by Trevor J. Wilkieson et al.
ORIGINAL RESEARCH ARTICLE Open Access
Coronary artery calcification, cardiovascular
events, and death: a prospective cohort
study of incident patients on hemodialysis
Trevor J. Wilkieson1, M. Omair Rahman2, Azim S. Gangji1,2, Maurice Voss3, Alistair J. Ingram1, Nischal Ranganath1,
Charlie H. Goldsmith2,4, Cathy Z. Kotsamanes1, Mark A. Crowther1, Christian G. Rabbat1 and Catherine M. Clase1,2*
Abstract
Background: Coronary calcification in patients with end-stage renal disease (ESRD) is associated with an increased
risk of cardiovascular outcomes and death from all causes. Previous evidence has been limited by short follow-up
periods and inclusion of a heterogeneous cluster of events in the primary analyses.
Objective: To describe coronary calcification in patients incident to ESRD, and to identify whether calcification
predicts vascular events or death.
Design: Prospective substudy of an inception cohort.
Setting: Tertiary care haemodialysis centre in Ontario (St Joseph’s Healthcare Hamilton).
Participants: Patients starting haemodialysis who were new to ESRD.
Measurements: At baseline, clinical characterization and spiral computed tomography (CT) to score coronary
calcification by the Agatston-Janowitz 130 scoring method. A primary outcome composite of adjudicated stroke,
myocardial infarction, or death.
Methods: We followed patients prospectively to identify the relationship between cardiac calcification and
subsequent stroke, myocardial infarction, or death, using Cox regression.
Results: We recruited 248 patients in 3 centres to our main study, which required only biochemical markers. Of
these 164 were at St Joseph’s healthcare, and eligible to participate in the substudy; of these, 51 completed CT
scanning (31 %). Median follow up was 26 months (Q1, Q3: 14, 34). The primary outcome occurred in 16 patients; 11 in
the group above the median and 5 in the group below (p = 0.086). There were 26 primary outcomes in 16 patients; 20
(77 %) events in the group above the coronary calcification median and 6 (23 %) in the group below (p = 0.006). There
were 10 deaths; 8 in the group above the median compared with 2 in the group below (p = 0.04). The hazard ratios for
coronary calcification above, compared with below the median, for the primary outcome composite were 2.5 (95 % CI
0.87, 7.3; p = 0.09) and 1.7 (95 % CI 0.55, 5.4; p = 0.4), unadjusted and adjusted for age, respectively. For death, the
hazard ratios were 4.6 (95 % CI 0.98, 21.96; p = 0.054) and 2.4 (95 % CI 0.45, 12.97; p = 0.3) respectively.
Limitations: We were limited by a small sample size and a small number of events.
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Conclusions: Respondent burden is high for additional testing around the initiation of dialysis. High coronary
calcification in patients new to ESRD has a tendency to predict cardiovascular outcomes and death, though effects are
attenuated when adjusted for age.
Keywords: End stage renal disease, Coronary artery calcification, Hemodialysis, Death, Myocardial infarction,
Cardiovascular outcome
Abrégé
Contexte: La calcification de l'artère coronaire chez les patients atteints d’insuffisance rénale terminale (IRT) est
associée à un risque accru de troubles cardiovasculaires et de mortalité, toutes causes confondues. Les données
précédemment recueillies se limitaient à un suivi de courte durée, de même qu’à l’inclusion de séries d’accidents
non liés lors de l’analyse préliminaire.
Objectifs: Décrire la calcification de l'artère coronaire chez les patients atteints d’IRT et déterminer si la calcification
de l'artère coronaire peut prédire des accidents vasculaires et la mort.
Type d’étude: Sous-étude prospective de cohorte selon le mode d'installation.
Cadre: Une unité de soins tertiaires en dialyse, en Ontario (St Joseph’s Healthcare Hamilton).
Participants: Des patients qui sont nouvellement atteints d’IRT et qui entament une hémodialyse.
Mesures: En début de traitement, une caractérisation clinique et une tomodensitométrie (TDM) hélicoïdale qui
permettent de mesurer la calcification de l'artère coronaire sur 130, selon l’échelle d’Agatston-Janowitz. L’indicateur
principal des résultats comprend l’AVC, l’infarctus du myocarde ou la mort.
Méthodes: Nous avons suivi les patients de manière prospective, afin de cibler la relation entre la calcification de
l'artère coronaire et l’AVC, l’infarctus du myocarde ou la mort subséquente, en utilisant la régression de Cox.
Résultats: Nous avons recruté 248 patients dans trois unités, dans le cadre de l’étude principale, qui ne requérait
que des biomarqueurs chimiques. De ces patients, 164 étaient de St Joseph’s Healthcare, et étaient admissibles à la
sous-étude; 51 avaient effectué une tomographie par ordinateur (31 %). Le suivi médian s’étendait sur 26 mois
(Q1, Q3: 14, 34). L’indicateur principal a été observé chez 16 patients; 11 dans le groupe se trouvant au-dessus de la
médiane, et 5 dans le groupe inférieur (p?=?0,086). On a observé 26 indicateurs principaux chez 16 patients; 20
(77 %) accidents dans le groupe se trouvant au-dessus de la médiane en ce qui a trait à la calcification et 6 (23 %)
dans le groupe inférieur (p?=?0,006). Il y a eu 10 décès; 8 dans le groupe se trouvant au-dessus de la médiane et 2
dans le groupe inférieur (p?=?0,04). Les taux de risque de calcification de l'artère coronaire se trouvant au-dessus et
sous la médiane, pour les indicateurs principaux, étaient respectivement de 2,5 (95 % IC 0,98; 21,96; p?=?0,054) et
2,4 (95 % IC 0,45, 12,97; p?=?0,3).
Limites de l’étude: Nous avons été limités par la taille restreinte de l’échantillon, de même que par le petit
nombre d’accidents.
Conclusion: Le fardeau du répondant repose sur des examens supplémentaires au moment de commencer la
dialyse. Un fort taux de calcification de l’artère coronaire chez les patients nouvellement atteints d’IRT tend à
prédire des accidents cardiovasculaires et la mort, bien que les effets soient atténués après révision en fonction
de l'âge.
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Background
End-stage renal disease (ESRD) affects over 36,000
Canadians, over 546,000 patients in the US, and is
currently an international health problem; the major-
ity are treated with hemodialysis (HD) [1, 2]. Cardio-
vascular death is the most common cause of death in
patients with ESRD [3]. Low glomerular filtration rate
causes impaired phosphate excretion which may lead
to excess secretion of fibroblast growth factor 23
(FGF23). FGF23 may cause reduced 1,25(OH)2D,
which in turn is implicated in hyperplasia of the para-
thyroid gland and increased parathyroid hormone
(PTH) [4]. These and other factors lead to an active
process of calcification of atherosclerotic plaque and
of the media of large vessels, including the coronary
arteries [5]. Cross sectional evidence has shown that
in patients with kidney disease, high coronary calcifi-
cation scores correlate with many risk factors for
death including older age, diabetes, HD vintage, and
lower estimated glomerular filtration rate [6–8]. Base-
line serum alkaline phosphatase, PTH, and serum cal-
cium also tend to be associated with higher coronary
calcification scores in patients on HD [7–9].
Prospective studies have shown that patients on main-
tenance HD with high coronary calcification have an in-
creased risk of cardiovascular events and death from all
causes compared with those with low or no coronary
calcification [8–11]. Similar findings were seen in pa-
tients with chronic kidney disease (CKD) who were not
on HD [12]. Evidence is limited by short follow-up pe-
riods [8–10] as well as the inclusion of events of varying
severity and clinical importance in a single composite
outcome [8, 12]. Some studies have not explicitly adjudi-
cated subjective outcomes [8, 10, 12], or included all pa-
tients enrolled in the primary analysis [9, 10].
Two previous prospective studies enrolled incident
patients on hemodialysis [13–15], but did not report car-
diovascular outcomes. We aimed to conduct a prospect-
ive evaluation of an incident cohort of patients starting
hemodialysis as their first ESRD treatment modality, and
to examine the patients’ coronary calcification scores as
a predictor for a rigorously defined and adjudicated
homogenous cluster of outcomes: stroke, myocardial in-
farction, and death from all causes.
Methods
This was a sub-study of the Canadian Longitudinal
Thrombosis in End-Stage Renal Disease (LONG) study,
which was a multi-centre prospective cohort involving 4
HD centres in Ontario. We studied those patients re-
cruited from the St Joseph’s Healthcare Hamilton
(SJHH) outpatient dialysis centre who consented to a
spiral computed tomography (CT) scan. (Spiral CT was
not available in the other centres at the time.) We
recruited patients with ESRD between October 2004 and
October 2007, and followed them until May 2008.
(Funding problems, and interruptions in the continuity
of investigators and staff prevented our following the pa-
tients longer, and delayed our analysis and publication of
the data.) Inclusion criteria were the following: informed
consent, at least 18 years of age, and on incident HD,
which was defined as being on HD between 30 and 90
days. Exclusion criteria were: anticipated renal recovery,
in the intensive care unit throughout the recruitment
period, scheduled live-donor kidney transplantation
within 6 months, difficulty in communication due to
language, cognitive disability, speech or hearing impair-
ments, or lack of informed consent. For this calcification
substudy there were further exclusions of prior stenting
and valve replacement, and current heart rate above 100.
This study was approved by the St Joseph’s Healthcare
Hamilton research ethics board.
The clinical assessment consisted of patient interviews,
physical examinations, and review of in-patient and out-
patient records. We characterized patients in terms of
age, sex, diabetes, blood pressure (mean of three read-
ings sitting, pre-midweek dialysis), and baseline cardio-
vascular events including myocardial infarction,
coronary artery bypass graft, percutaneous coronary
intervention, atrial fibrillation, deep vein thrombosis,
and pulmonary embolism. We documented medications
(including type of phosphate binder, warfarin use, and
active vitamin D compounds) along with laboratory in-
vestigations (serum calcium, phosphorus, albumin, alka-
line phosphatase, glucose, haemoglobin A1c (HbA1C),
haemoglobin, C-reactive protein, uric acid, intact PTH,
urinary reduction ratio, leukocytes, and platelets). La-
boratory testing was performed before a mid-week dialy-
sis session.
The primary outcome for the present study was a com-
posite of stroke, myocardial infarction, or death. The sec-
ondary outcomes included event rate and cause of death
(cardiovascular or from all other causes). Two physicians
adjudicated each event according to prespecified defini-
tions and reached consensus on disagreements.
Calcification scoring
We determined coronary calcification scores using a
spiral CT scan. Spiral CT has been shown to have a low
intra-reader variability of 0.9 % (0 % median) in examin-
ing patients with ESRD for coronary calcification [16].
Coronary calcification was scored according to the
Agatston-Janowitz 130 scoring method, in which the
area of each calcified lesion that has peak attenuation
greater than 130 Hounsfield units (HU) is multiplied by
a density factor [17]. If between 130 and 199 HU, 200
and 299 HU, 300 and 399 HU, or > 400 HU, the density
factor is 1, 2, 3, or 4, respectively [17]. Readings were
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performed by one experienced radiologist (MV), blinded
to baseline clinical data. Researchers and clinicians were
blinded to the results for the duration of the study so
that the calcification score could not influence care.
Statistical analysis
We made an a priori decision to analyze patients
grouped as above, or below, the coronary calcification
score median. We calculated the mean and standard de-
viation (SD) for all baseline continuous variables and the
frequency and percentage of all categorical variables. We
compared continuous variables at baseline across groups
with t tests and compared categorical variables using chi
squared. In our primary analysis we used adjusted and
unadjusted survival analyses to measure the association
between a coronary calcification score above or below
the median and the occurrence of a primary outcome,
censoring at the end of the study or if patients moved
away or received renal transplants. (We did not censor
at transfer to peritoneal dialysis). In our secondary ana-
lyses we measured the associations between coronary
calcification group and each component of the event
cluster. We used the Kaplan-Meier method to create
and graph survival curves, and Cox regression, both
unadjusted and adjusted for age to assess differences
between groups. We compared rates of events per
person-time using Poisson-based methods. All analyses
were conducted using SPSS version 18.0 for Windows
(Chicago, IL, USA).
Results
Of the 246 patients recruited for the LONG study, 164
were from SJHH and 51 (31 %) of these patients con-
sented to a spiral CT. Median follow up time was 26
months (Q1, Q3: 14, 34). There was no loss to follow up.
Mean patient age was 59 years (SD 13.4) old, 29 %
were male; the most common cause of ESRD was dia-
betes (61 %). The median coronary calcification score in
the sample was 642. Patients with coronary calcification
scores above the median (n = 26) were older, had higher
serum albumin levels, and had had more deep vein
thrombosis and pulmonary embolism events compared
with those below the median (n = 25) (Table 1). There
were no significant differences between groups in serum
calcium, serum phosphorus, alkaline phosphatase, C-
reactive protein, international normalized ratio, urea
reduction ratio, presence of liver disease, presence of
diabetes, blood pressure, or warfarin use.
There were 26 primary outcomes (Table 2). Of these,
77 % of events occurred in the patients above the me-
dian coronary calcification score (20 outcomes in 586
patient months) compared with 23 % of events in the
patients below the median (6 outcomes in 642 patient
months) (p = 0.006). There were a total of 10 deaths: 8
in the group above the median and 2 in the group below
the median (p = 0.04) (Table 3). Of these, 5 were cardio-
vascular deaths: 4 in the group above the median and 1
in the group below the median (p = 0.2). The 26 primary
events occurred in 16 patients: 11/26 (42 %) of these pa-
tients were in the group above the coronary calcification
median compared with 5/25 (20 %) in the group below
the median (p = 0.086). By Cox regression, the hazard
ratio for coronary calcification above, compared with
below the median, was 2.5 (95 % CI 0.87, 7.3; p = 0.09)
(Fig. 1). When adjusted for age, the hazard ratio was 1.7
(95 % CI 0.55, 5.4; p = 0.4). For myocardial infarction
alone, the hazard ratios for above, compared with below
the median, were 2.5 (95 % CI 0.65, 9.9; p = 0.2) and 1.7
(95 % CI 0.4, 7.3; p = 0.5), unadjusted and adjusted for
age, respectively. For death, the hazard ratios were 4.6
(95 % CI 0.98, 21.96; p = 0.054) and 2.4 (95 % CI 0.45,
12.97, p = 0.3) respectively.
Discussion
The direction of our data suggests that coronary artery
calcification may predict death, although this did not
reach statistical significance. Additionally, there were ten-
dencies towards association with future myocardial infarc-
tion, total events and event-free survival. Our findings
suggest an increased risk of CV events, CV death, and
death from all causes associated with having a higher cor-
onary calcification score. When adjusted for age, the haz-
ard ratio decreases from 2.5 (95 % CI 0.87, 7.3) to 1.7
(95 % CI 0.55, 5.4), suggesting that age may be a
confounder.
Our results are consistent with one prospective study
of 103 patients on HD with a follow up of 44 months
that demonstrated a tendency towards increased relative
risk for death of 2.7 (95 % CI 0.9, 8.3) for patients on
hemodialysis having coronary calcification scores above
200 compared to those with scores below 200 (p = 0.08)
[11]. Similarly, another prospective study examining 56
prevalent patients on HD over 15 months [8] found that
patients with coronary calcification scores above the me-
dian had a relative risk for cardiovascular events of 2.6
(95 % CI 1.2, 5.5; p = 0.01), a relative risk for cardiovas-
cular death of 3.1 (95 % CI 0.7, 14.3; p = 0.14), and a
relative risk for death from all causes of 3.3 (95 % CI 1.4,
7.8; p = 0.007) [8]. However, this study used a composite
for cardiovascular events that consisted of a heteroge-
neous mix of hard and soft outcomes including angina,
myocardial infarction, percutaneous coronary interven-
tion, CABG, severe valve disease, heart failure, and
stroke [8]. In a 24-month prospective study of 117
patients with CKD who were not on HD, patients
with coronary calcification scores ≥ 400 had an in-
creased risk of cardiovascular events (a heterogeneous
cluster of acute myocardial infarction, stroke, angina,
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Table 1 Baseline characteristics of participants
Baseline Characteristics Coronary calcification
below median (n = 25)
Coronary calcification
above median (n = 26)
Total (N = 51) P value Missing data
Age, y (mean; SD) 54.1 (12.7) 63.2 (12.7) 58.7 (13.4) 0.014 0
Gender, male (n; %) 15 (60) 21 (80) 36 (70.6) 0.104 0
Duration of HD, d (mean; SD) 144.6 (67.8) 145.8 (55.7) 145.2 (61.3) 0.065 0
Coronary calcification score (mean; SD) 102 (164.8) 2520.9 (1563.8) 1335 (1651) <0.001 0
Calcium, mmol/L (mean; SD) 2.3 (0.2) 2.3 (0.3) 2.3 (0.2) 0.800 1
Phosphorus, mmol/L (mean; SD) 1.8 (0.4) 1.8 (0.6) 1.8 (0.5) 0.857 1
Albumin, g/L (mean; SD) 39.4 (2.9) 36.2 (5.2) 37.8 (4.5) 0.011 1
Alkaline phosphatase, U/L (mean; SD) 99.0 (51.9) 110.0 (44.5) 104.2 (48.2) 0.490 13
Glucose, mmol/L (mean; SD) 8.8 (7.2) 9.3 (6.9) 9.0 (7.0) 0.790 1
HbA1C (mean; SD) 0.07 (0.02) 0.07 (0.02) 0.07 (0.02) 0.716 28
C reactive protein, mg/L (mean; SD) 5.5 (8.2) 31.8 (46.1) 19.3 (35.7) 0.091 30
Intact PTH, pmol/L (mean; SD) 104.5 (129.0) 104.3 (83.0) 104.4 (108.8) 0.994 10
Uric acid, μmol/L (mean; SD) 380.4 (75.5) 372.8 (78.5) 376.6 (76.1) 0.750 9
URR (mean; SD) 65.4 (16.1) 66.2 (7.3) 65.8 (12.3) 0.834 2
Hemoglobin, g/L 112.76 (12.30) 119.69 (11.31) 116.29 (12.20) 0.041 0
Comorbidities
COPD (n; %) 9 (36 %) 6 (23 %) 15 (29.4) 0.311 0
Liver disease (n; %) 2 (8 %) 0 (0 %) 2 (3.9) 0.141 0
Diabetes (n; %) 13 (52 %) 18 (69 %) 31 (60.8) 0.208 0
Hypertension (n; %) 23 (92 %) 24 (92 %) 47 (92.2) 0.967 0
Systolic blood pressure, mmHg (mean; SD) 147.6 (23.2) 145.4 (22.7) 146.5 (22.8) 0.737 0
Diastolic blood pressure, mmHg (mean; SD) 78.8 (15.9) 80.2 (14.2) 79.5 (14.9) 0.742 0
Baseline Cardiovascular Disease
Myocardial infarction (n; %) 4 (16 %) 7 (27 %) 11 (21.6) 0.343 0
CABG (n; %) 2 (8 %) 3 (11 %) 5 (9.8) 0.671 0
Percutaneous coronary intervention (n; %) 1 (4 %) 5 (19 %) 6 (11.8) 0.091 0
Atrial fibrillation (n; %) 2 (8 %) 5 (19 %) 7 (13.7) 0.244 0
DVT (n; %) 5 (20 %) 0 (0 %) 5 (9.8) 0.016 0
Pulmonary embolism (n; %) 4 (16 %) 0 (0 %) 4 (7.8) 0.034 0
Cause of ESRD
Glomerulonephritis (n; %) 11 (44 %) 2 (8 %) 13 (25.5) 0.003 0
Polycystic kidney disease (n; %) 2 (8 %) 1 (4 %) 3 (5.9) 0.529 0
Diabetes mellitus (n; %) 6 (24 %) 12 (46 %) 18 (35.3) 0.098 0
Hypertension (n; %) 5 (20 %) 10 (38 %) 15 (29.4) 0.148 0
Other (n; %) 1 (4 %) 1 (4 %) 2 (3.9) 0.977 0
Medications
Calcium carbonate (n; %) 17 (68 %) 18 69 % 35 (68.6) 0.925 0
Sevelamer (n; %) 1 (4 %) 0 (0 %) 1 (2.0) 0.303 0
Bisphosphonates (n; %) 1 (4 %) 0 (0 %) 1 (2.0) 0.303 0
Warfarin (n; %) 4 (16 %) 5 (19 %) 9 (17.6) 0.762 0
Alfacalcidol (n; %) 14 (56 %) 9 (35 %) 23 (45.1) 0.125 0
HD hemodialysis, CABG coronary artery bypass grafting, DVT deep venous thrombosis, ESRD End-stage renal disease. Missing data 0-2 % with the exceptions of
alkaline phosphatase (25 %), Hb:A1C ratio (55 %), C reactive protein (59 %), INR (29 %), iPTH (20 %), and uric acid (18 %)
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arrhythmia, uncontrolled hypertension and cardiac failure)
(HR = 3.53; 95 % CI: 1.03, 12.06; p = 0.04), and hospitaliza-
tions (HR = 4.05; 95 % CI 1.4, 11.5; p = 0.009) [12]. Cox re-
gression was not conducted for deaths as there were no
deaths in patients with coronary calcification scores < 400
compared with 4 in the group ≥ 400 (p = 0.002) [12]. An-
other study of 64 patients with ESRD on maintenance HD
followed for 18 months found, in its secondary analysis,
that cardiovascular outcomes occurred in 35 % of patients
with a coronary calcification score > 10 compared, and
in 0 % of patients with a coronary calcification score < 10
[10]. Patients who experienced a cardiovascular event had
a higher mean coronary calcification score (1017 SD 975)
than those who had not (129 SD 336) (p = 0.02) [10]. As
in other studies, the cardiovascular outcome composite
included both hard and soft outcomes (new-onset angina,
myocardial infarction, angioplasty, and coronary artery by-
pass surgery) [10]. Another prospective study in 127 inci-
dent patients on HD followed for 18 months found a
mean baseline coronary calcification score of 391 (SD
693) in patients alive at the end of the study and 1373 (SD
2034) in the 34 patients who had died (p <0.0001) [13].
Cardiovascular outcomes and risk were not reported [13].
One previous investigation of incident patients on
HD reported a proportional increase in mortality with
increasing coronary calcification, but did not report
cardiovascular outcomes [14, 15]. This study, a clinical
trial investigating the effect of the non-calcium phos-
phate binder sevalamer hydrochloride compared with
calcium-containing phosphate binders on progression
of coronary artery calcification in patients new to
hemodialysis, observed progression of CAC in patients
with baseline CAC >30, and that patients who were
randomized to calcium-containing phosphate binders
had a more rapid rate of progression that those
randomized to sevalamer (p = 0.056 at 12 months; p = 0.01
at 18 months) [14].
Coronary calcification above the median was associ-
ated with older age, higher alkaline phosphatase, and
higher hemoglobin, and a tendency toward a higher
prevalence of diabetes as cause of ESRD (but not a
higher prevalence of current diabetes). No differences
were seen in serum calcium, phosphorus, calcium-
phosphate product, iPTH, urea reduction ratio, or
current warfarin use. Cross-sectional studies and baseline
associations have shown consistent correlations between
coronary calcification score and age [9, 11, 13, 18], dur-
ation of diabetes [6], HD vintage [7–9, 11], alkaline phos-
phatase [7], and fetuin-A [9]. Associations have been
inconsistent for coronary calcification score and serum in-
tact PTH [9, 10, 13], C-reactive protein [7, 9, 10, 13],
serum calcium [7, 9, 18], serum creatinine [7, 13], choles-
terol [7, 18], diabetes [7, 11, 18], smoking [7, 18], and
hypertension [11, 18].
This study is one of the few that has looked at coron-
ary artery calcification in incident ESRD, and is the only
one, to our knowledge, that has prospectively examined
both cardiovascular outcomes and death in this popula-
tion. Much of the prior evidence has been derived from
prevalent patients on maintenance HD [7–11, 18]. We
had a well-characterized population at baseline, with an
a priori decision to group patients on the basis of having
a coronary calcification score above and below the me-
dian. Our composite outcome was a homogenous event
cluster of serious, adjudicated cardiovascular events
(stroke, MI), cardiovascular death, and death from all
causes. We learned that patients at this stage of illness
are very much deterred by the respondent burden of
testing that requires an additional appointment. We
were limited by a small sample size and a small number
Table 2 Outcomes in the 51 patients over 1228 patient months
Outcome Coronary calcification
below median (n = 25)
Coronary calcification
above median (n = 26)
Total (N = 51) P value
Primary outcomes (n) 6 20 26 0.006b
Total patients with events (n) 5 (20 %) 11 (42 %) 16 0.086a
Myocardial infarction (n) 3 10 13 0.054b
Stroke (n) 1 2 3 0.58b
Death (n) 2 8 10 0.041a
aChi squared
bPoisson
Table 3 Causes of death
Cause of death Coronary calcification
below median (n = 25)
Coronary calcification
above median (n = 26)
Total (N = 51) P value
Cardiovascular (n; %) 1 (4 %) 4 (15 %) 5 0.172
Other (n; %) 1 (4 %) 4 (15 %) 5 0.172
Death total (n; %) 2 (8 %) 8 (31 %) 10 0.041
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of events and thus, we were limited in the ability to per-
form multivariable adjustments. The small sample size
may have led to type II error in the absence of associ-
ation between biochemical markers, baseline clinical sta-
tus and cardiac calcification. Patients who consented to
this calcification substudy were younger than those in
the study as a whole, and though this should not
threaten the internal validity of the findings, it is a re-
minder of the challenges of observational studies with
substantial respondent burden (such as the additional
visit and risk associated with CT in this study) in pa-
tients already heavily burdened by an intrusive disease
and an intrusive treatment.
Conclusion
We conclude that, within the limits of our small sam-
ple size, our data are consistent with those of others
showing that in incident patients with ESRD, coron-
ary artery calcification predicts cardiovascular events
and death. Coronary calcification was highly prevalent
at baseline in this study, even though the patients
were younger than the mean for patients starting
dialysis in most of the developed world. Future re-
search should aim to understand the mechanism of
calcification in patients with chronic kidney disease
before and after ESRD as well as evaluate therapeutic
interventions to prevent coronary calcification or
ameliorate its effects. We hope that this work will be
a useful addition to future meta-analyses and will also
help to provide information on baseline central ten-
dencies and distributions to others who plan trials in
this area. We also note that it may be challenging to
recruit patients to studies that involve a special ap-
pointment in patients who have just started dialysis.
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